Catalent enters AAV vector production agreement with IVERIC bio

By Maggie Lynch

- Last updated on GMT

(Image: Getty/krtiacanut)
(Image: Getty/krtiacanut)

Related tags Viral vector Production line Clinical trial Trial supply management Clinical research Catalent Catalent pharma solutions

Catalent is producing AAV vectors for the preclinical and clinical trial supply of Iveric bio’s lead drug candidates.

Iveric bio, which focuses on the development of gene therapy solutions for orphan inherited retinal diseases, will work with Catalent Biologics subsidiary, Paragon Gene Therapy.

Catalent acquired Paragon for $1.2bn in May 2019, for the production of preclinical and clinical trial supply of adeno-associated viral (AAV) vectors.

Together, the companies will produce the AAV vectors needed for Iveric’s drug therapy products IC-100 and IC-200 as they move into the clinic. Clinical trials for IC-100 are expected to begin in 2020 and 2021 for IC-200.

IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa, and IC-200 for the treatment of BEST1 related retinal diseases, which will be entering Phase I/II clinical trials within the next two years.

A spokesperson for Catalent Biologics told us that through this deal, Iveric bio will have access to Paragon’s manufacturing capabilities and capacity at Catalent’s site in Baltimore, Maryland.

No financial terms have been disclosed.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars